Medicines Alone Held Their Own Against Invasive Treatment for Heart Attacks in Older Adults

CATEGORY: HEART & CIRCULATION

A heart attack at 82 arrives with a decision attached. Medicines alone, or medicines plus a thin tube threaded up to the heart to find and reopen the blockage? In a British randomized trial of 1,518 patients aged 75 and older, the two routes finished in much the same place: 26.3% of the medicines-alone group versus 25.6% of the invasive group went on to die of a cardiovascular cause or have another heart attack over roughly four years, a difference small enough to be chance.¹ The trial, SENIOR-RITA, recruited precisely the patients earlier heart-attack research tended to leave out.

Average Age 82, the Oldest 103

The form of heart attack under study was non-ST-elevation myocardial infarction, the commoner kind, in which a coronary artery is severely narrowed or briefly blocked rather than suddenly sealed shut. Across 48 hospitals in England and Scotland, researchers signed up 1,518 such patients aged 75 or older. Average age was 82. The oldest was 103, nearly half were women, and four in five were prefrail or frail. A randomization list, not a doctor and not a patient, sorted each of them into one of two strategies. Both groups received the full set of recommended heart medicines. One group also underwent coronary angiography, in which dye and X-rays map the blockages through a tube fed from the wrist or groin, much as a plumber runs an inspection camera down a pipe to find the clog. Where the pictures warranted it, blood flow was then restored with a stent (a small mesh tube that props the artery open) or with bypass surgery. Because chance picked who got the procedures, any gap over the median 4.1 years of follow-up belongs to the strategy itself.

Ninety Percent Got the Camera, Half Got a Repair

In the invasive group, 90% actually had the angiography and about half went on to a procedure restoring blood flow. The main measure did not budge. Cardiovascular death or a new nonfatal heart attack struck 25.6% with invasive care and 26.3% with medicines alone, a hazard ratio of 0.94 with a confidence interval running from 0.77 to 1.14. Cardiovascular death on its own was also flat, 15.8% versus 14.2%. The procedures proved notably safe at these ages: complications hit fewer than 1% of patients, and bleeding was no more common in the invasive group. The lead investigator said plainly that the invasive strategy did not reduce the trial’s primary endpoint, while adding that it looked safe and carried some benefits. Those benefits were real but narrower than hoped. Later nonfatal heart attacks came to 11.7% of the invasive group against 15.0% of the medicines-alone group, about three fewer per hundred patients, and the need for a later unplanned artery-opening procedure dropped from 13.7% to 3.9%. What the procedures did not do at this age was help more people survive.

Eight Trials, the Same Split Verdict

A pooled analysis of eight randomized trials covering 3,887 older patients with this kind of heart attack landed in the same split place. No difference in deaths from any cause (risk ratio 1.05, confidence interval 0.93 to 1.17). Fewer repeat heart attacks (risk ratio 0.70), and far fewer later procedures, with the invasive approach. Somewhat more severe bleeding across the pooled trials, too (risk ratio 1.43).² So the evidence now describes a trade rather than a winner: at this age the invasive route does not extend life, it lowers the odds of another heart attack and of an urgent procedure later, and the wider pool shows a bleeding cost attached.

Key Takeaways

• Among adults 75 and older with the commoner type of heart attack, adding invasive artery-opening care on top of medicines left the combined rate of cardiovascular death or repeat heart attack unchanged, 25.6% versus 26.3% over about four years.
• Invasive care did cut later nonfatal heart attacks (11.7% versus 15.0%) and later unplanned procedures (3.9% versus 13.7%), and procedural complications were rare even in the very old.
• Eight pooled randomized trials show the same shape: no survival difference, fewer repeat heart attacks, somewhat more severe bleeding on the invasive side.

References

1. Kunadian V, Mossop H, Shields C, et al. Invasive Treatment Strategy for Older Patients with Myocardial Infarction. New England Journal of Medicine. 2024;391(18):1673–1684. link
2. Vats V, Shahjehan RD, Kumar BS, et al. Invasive treatment strategy for older patients with non-ST-elevation acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine. 2025;12:1638932. link